Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.
复制标题
DOI:
10.3389/fonc.2022.925818
复制
发表时间:
2022
影响因子:
4.7
通讯作者:
Mark, Tomer M.
中科院分区:
文献类型:
--
作者:
Keller, Alana L.;Sherbenou, Daniel W.;Forsberg, Peter A.;Mark, Tomer M.
Multiple myeloma is an incurable hematologic malignancy. The typical disease course for myeloma patients is characterized by initial response to treatment followed by eventual development of resistance. Subsequent cycles of remission and relapse proceed as long as patients have new lines of therapy available to them. This reality has prompted development of many novel immunotherapeutics. Many of these drugs exploit the cytotoxic capabilities of the patients’ own T cells, effectively redirecting them to myeloma cells that are otherwise evading immune attack. Approaches including CAR T cell therapy and bispecific antibodies have displayed impressive efficacy in clinical trials for myeloma patients. This review examines the different approaches that utilize T cells in multiple myeloma therapy and investigates the benefits and risks of these exciting new strategies.
登录
查看更多内容
影响因子:
20.3
作者:
Badros, Ashraf;Hyjek, Elizabeth;Singh, Zeba
通讯作者:
Singh, Zeba
影响因子:
14.8
作者:
Ali, Muhammad;Foldvari, Zsofia;Olweus, Johanna
通讯作者:
Olweus, Johanna
DOI:
10.1158/1078-0432.ccr-20-3770
发表时间:
2021-10-15
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
通讯作者:
--
影响因子:
28.4
作者:
Cowan AJ;Allen C;Barac A;Basaleem H;Bensenor I;Curado MP;Foreman K;Gupta R;Harvey J;Hosgood HD;Jakovljevic M;Khader Y;Linn S;Lad D;Mantovani L;Nong VM;Mokdad A;Naghavi M;Postma M;Roshandel G;Shackelford K;Sisay M;Nguyen CT;Tran TT;Xuan BT;Ukwaja KN;Vollset SE;Weiderpass E;Libby EN;Fitzmaurice C
通讯作者:
Fitzmaurice C
影响因子:
20.3
作者:
Bladé, J;Rosiñol, L;San Miguel, J
通讯作者:
San Miguel, J